BACKGROUND: 6-Thioguanine (6-TG) is efficacious in patients with Crohn's Disease (CD) failing conventional immunosuppression but there are reports of hepatotoxicity. We report our experience of the safety and efficacy of 6-TG in a series of patients with CD. METHODS: A retrospective study of patients with CD who failed thiopurines +/- methotrexate between 2001 and 2006 was performed. Indications for 6-TG were; active disease, to allow infliximab withdrawal, steroid sparing, or fistula closure. Patients underwent regular review and those treated longer than 1 year were advised to have liver magnetic resonance imaging (MRI) and liver biopsy. RESULTS: All 30 patients treated with 6-TG during the period were included. The median dose and duration of 6-TG was 40 mg daily and 21.5 months, respectively. Initial clinical response was achieved in 18/30 (60%). Eleven of 29 (38%) (1 unrelated death) remained in remission at a median 44 months follow-up. Seven of 30 (23%) discontinued 6-TG due to adverse effects; 7/30 (23%) patients developed abnormal liver function tests (LFTs) during treatment, mostly transient and mild. One patient developed a portal hypertensive syndrome resolving on cessation of 6-TG. Of 11 liver biopsies, none showed nodular regenerative hyperplasia (NRH). The median red blood cell 6-thioguanine nucleotide (6-TGN) level was 807 pmol/10(8). CONCLUSIONS: 6-TG has good clinical efficacy for third-line immunosuppression in CD but hepatotoxicity remains a concern. However, previous reports of NRH in 6-TG-treated inflammatory bowel disease patients have not been substantiated by this cohort.
BACKGROUND:6-Thioguanine (6-TG) is efficacious in patients with Crohn's Disease (CD) failing conventional immunosuppression but there are reports of hepatotoxicity. We report our experience of the safety and efficacy of 6-TG in a series of patients with CD. METHODS: A retrospective study of patients with CD who failed thiopurines +/- methotrexate between 2001 and 2006 was performed. Indications for 6-TG were; active disease, to allow infliximab withdrawal, steroid sparing, or fistula closure. Patients underwent regular review and those treated longer than 1 year were advised to have liver magnetic resonance imaging (MRI) and liver biopsy. RESULTS: All 30 patients treated with 6-TG during the period were included. The median dose and duration of 6-TG was 40 mg daily and 21.5 months, respectively. Initial clinical response was achieved in 18/30 (60%). Eleven of 29 (38%) (1 unrelated death) remained in remission at a median 44 months follow-up. Seven of 30 (23%) discontinued 6-TG due to adverse effects; 7/30 (23%) patients developed abnormal liver function tests (LFTs) during treatment, mostly transient and mild. One patient developed a portal hypertensive syndrome resolving on cessation of 6-TG. Of 11 liver biopsies, none showed nodular regenerative hyperplasia (NRH). The median red blood cell 6-thioguanine nucleotide (6-TGN) level was 807 pmol/10(8). CONCLUSIONS:6-TG has good clinical efficacy for third-line immunosuppression in CD but hepatotoxicity remains a concern. However, previous reports of NRH in 6-TG-treated inflammatory bowel diseasepatients have not been substantiated by this cohort.
Authors: Mark G Ward; Kamal V Patel; Viraj C Kariyawasam; Rishi Goel; Ben Warner; Tim R Elliott; Paul A Blaker; Peter M Irving; Anthony M Marinaki; Jeremy D Sanderson Journal: United European Gastroenterol J Date: 2016-08-01 Impact factor: 4.623
Authors: Pedro R Chocair; Precil Diego Miranda de Menezes Neves; Sara Mohrbacher; Maurilio Pacheco Neto; Victor A H Sato; Érico S Oliveira; Leonardo V Barbosa; Alessandra M Bales; Fagner Pereira da Silva; Américo L Cuvello-Neto; John A Duley Journal: Front Immunol Date: 2022-06-10 Impact factor: 8.786
Authors: Miloslav Kverka; Pavel Rossmann; Helena Tlaskalova-Hogenova; Klara Klimesova; Bindia Jharap; Nanne K de Boer; Rene M Vos; Adriaan A van Bodegraven; Milan Lukas; Chris J Mulder Journal: BMC Gastroenterol Date: 2011-05-05 Impact factor: 3.067
Authors: Melek Simsek; Debbie S Deben; Carmen S Horjus; Melanie V Bénard; Birgit I Lissenberg-Witte; Hans J C Buiter; Matthijs van Luin; Margien L Seinen; Chris J J Mulder; Dennis R Wong; Nanne K H de Boer; Adriaan A van Bodegraven Journal: Aliment Pharmacol Ther Date: 2019-05-16 Impact factor: 8.171
Authors: Ahmed B Bayoumy; Elsa L S A van Liere; Melek Simsek; Ben Warner; Aathavan Loganayagam; Jeremy D Sanderson; Simon Anderson; Jonathan Nolan; Nanne K de Boer; Chris J J Mulder; Azhar Ansari Journal: BMC Gastroenterol Date: 2020-09-11 Impact factor: 3.067